Specialty Pharmacy's Critical Role as Advanced Therapies Move Into the Community: Fran Gregory, PharmD, MBA

Why It Matters

The shift empowers community clinicians to deliver cutting‑edge treatments while specialty pharmacies mitigate operational complexity, accelerating patient access and equity across the healthcare system.

Key Takeaways

• Advanced therapies projected to triple from 61 to ~180 by 2030.
• Specialty pharmacies handle reimbursement, logistics, and data collection for community providers.
• High‑volume conditions like cardiovascular disease will outpace academic center capacity.
• Community providers face staffing and workflow challenges administering complex therapies.

Pulse Analysis

The pipeline of advanced therapies is moving beyond the confines of academic medical centers, driven by a surge in innovative modalities such as gene editing, bispecific antibodies, and engineered monoclonal antibodies. Analysts estimate the number of FDA‑approved products will triple within the next four years, reflecting both scientific breakthroughs and expanding indications for common diseases like heart failure and diabetes. This rapid diversification forces payers, providers, and manufacturers to rethink distribution models, as the traditional buy‑and‑bill approach strains under the weight of complex cold‑chain requirements and high upfront costs.

Specialty pharmacies have emerged as a critical bridge between manufacturers and community clinicians. Beyond medication dispensing, they now negotiate reimbursement, coordinate patient onboarding, manage infusion logistics, and capture longitudinal outcomes data essential for value‑based contracts. By centralizing these functions, specialty pharmacies reduce the operational overhead for physicians, allowing them to focus on clinical decision‑making. Their data‑analytics capabilities also feed real‑world evidence back to developers, accelerating post‑market surveillance and informing next‑generation trial designs.

For patients, this evolving ecosystem promises broader, more equitable access to life‑changing therapies. Community providers, equipped with specialty pharmacy support, can deliver treatments that were once limited to tertiary centers, reducing travel burdens and improving adherence. However, the transition also raises questions about reimbursement parity, data privacy, and the need for robust training programs. As the advanced therapy market matures, stakeholders must collaborate to standardize workflows, ensure transparent pricing, and maintain high standards of patient safety, thereby unlocking the full potential of these breakthrough medicines.